ADC Technology Market: Focus on ADC Linker and ADC Conjugation Technologies (2nd Edition) - Distribution by Generation of ADC Technology, Type of Conjugation, Type of Linker and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035
The antibody drug conjugates technology market is anticipated to grow at a CAGR of 15% during the forecast period 2023-2035
Antibody drug conjugates (ADCs) have emerged as a promising avenue in cancer therapy, providing an alternative to conventional treatments. Currently, around 14 ADCs have received approval from the USFDA, and over 420 are undergoing evaluations in various developmental stages. This class of biotherapeutics relies on a complex structure involving linkers binding cytotoxic payloads to antibodies. However, the complexity of ADC design poses challenges in ensuring overall effectiveness and tolerance of the molecule. Consequently, there is a pressing need for more sophisticated and potent ADC technologies to facilitate controlled assembly while maintaining safety and tolerability. ADC technologies encompass the modification and engineering of antibodies for conjugation with payloads or linker-drug moieties. Simultaneously, ADC linker technologies focus on structurally developing moieties that reliably link payloads to antibodies, ensuring desired payload delivery mechanics. These approaches are tailored to produce homogeneous ADCs with a high drug to antibody ratio (DAR), exhibiting enhanced stability and efficacy within the tumor micro-environment.
Homogeneous ADCs, facilitated by optimized linker technologies, display reduced immunogenicity, enabling targeted delivery of the linker-payload complex without adverse effects. Consequently, numerous startups and established entities have entered the domain, offering novel bioconjugation technologies, potent payloads, and advanced linker chemistries. Many of these players have engaged in licensing agreements to advance their ADC development initiatives. Notably, researchers and developers of ADCs actively seek expertise and experience from companies specializing in ADC linker and conjugation technologies. Driven by the escalating demand for ADCs, the market for ADC linker and conjugation technologies is projected to experience substantial growth in the forecast period.
Report Coverage
Antibody drug conjugates (ADCs) have emerged as a promising avenue in cancer therapy, providing an alternative to conventional treatments. Currently, around 14 ADCs have received approval from the USFDA, and over 420 are undergoing evaluations in various developmental stages. This class of biotherapeutics relies on a complex structure involving linkers binding cytotoxic payloads to antibodies. However, the complexity of ADC design poses challenges in ensuring overall effectiveness and tolerance of the molecule. Consequently, there is a pressing need for more sophisticated and potent ADC technologies to facilitate controlled assembly while maintaining safety and tolerability. ADC technologies encompass the modification and engineering of antibodies for conjugation with payloads or linker-drug moieties. Simultaneously, ADC linker technologies focus on structurally developing moieties that reliably link payloads to antibodies, ensuring desired payload delivery mechanics. These approaches are tailored to produce homogeneous ADCs with a high drug to antibody ratio (DAR), exhibiting enhanced stability and efficacy within the tumor micro-environment.
Homogeneous ADCs, facilitated by optimized linker technologies, display reduced immunogenicity, enabling targeted delivery of the linker-payload complex without adverse effects. Consequently, numerous startups and established entities have entered the domain, offering novel bioconjugation technologies, potent payloads, and advanced linker chemistries. Many of these players have engaged in licensing agreements to advance their ADC development initiatives. Notably, researchers and developers of ADCs actively seek expertise and experience from companies specializing in ADC linker and conjugation technologies. Driven by the escalating demand for ADCs, the market for ADC linker and conjugation technologies is projected to experience substantial growth in the forecast period.
Report Coverage
- The study examines the ADC technology market by analyzing ADC technology, conjugation type, linker type, and key geographical regions.
- An analysis is conducted on the factors influencing market growth, including drivers, restraints, opportunities, and challenges.
- Evaluation of potential advantages and barriers within the market is provided, along with insights into the competitive landscape for major market players.
- Revenue forecasts for market segments are presented concerning four significant regions.
- The executive summary encompasses essential insights gathered from extensive research, offering a comprehensive overview of the current landscape and future trajectory of the ADC linker and antibody conjugation technologies market. This includes an introduction to antibody drug conjugates (ADCs), emphasizing their components, mechanisms of action, and advantages over conventional therapies. The focus remains on the pivotal role played by ADC linker and conjugation technologies in ADC therapeutic development. The section provides an overview of various linker types, conjugation technologies, their specifications, and discusses challenges while presenting anticipated future trends.
- A comprehensive review of the ADC linker and conjugation technologies landscape is presented based on various parameters, including technology types, licensing availability, generation categorization, site specificity, conjugation methods, drug antibody ratio, compatible linker types, conjugation chemistry, and company profiles based on establishment year, size, and headquarters location.
- An in-depth analysis categorizes technology players into small, mid-sized, and large groups, assessing their strengths based on portfolio depth, technological competitiveness, and partnership activities, allowing companies to compare capabilities within and beyond their peer groups and identify opportunities for competitive advantage.
- Detailed profiles highlight prominent companies engaged in ADC linker and conjugation technologies, covering company overview, technology portfolio, recent developments, and future outlook.
- A thorough review of patents filed/granted for ADC linker and conjugation technologies between 2018-2023 includes parameters such as patent types, publication, and application years, jurisdiction, focus areas, CPC symbols, and patent valuation analysis, emphasizing leading patents based on citations.
- Analysis of partnerships formed between stakeholders for ADC technologies during 2014-2023 explores partnership types, partner categories, technological generations, therapeutic areas, active players, and geographical locations.
- A detailed examination of business models adopted by ADC technology providers covers partnership purposes, business strategies, investment types, amounts, and active players.
- An extensive analysis of over 85 ADC therapeutics developers likely to partner with ADC linker and conjugation technology companies evaluates based on establishment year, company size, portfolio, pipeline, and therapeutic area.
- A brand positioning analysis of leading antibody conjugation technology providers highlights current perceptions of their proprietary technologies based on experience, technology diversity, patents, and partnerships.
- A detailed case study investigates the ADC market, considering development stages, disease indications, therapeutic areas, treatment lines, dosing frequencies, antigen targets, developer details, and active players.
- Alteogen
- Ambrx
- Antikor
- Catalent Biologics
- Heidelberg Pharma
- Iksuda Therapeutics
- LegoChem Biosciences
- Mersana Therapeutics
- NBE-Therapeutics
- Seattle Genetics
- Sutro Biopharma
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2 Antibody Drug Conjugates (ADCs)
3.2.1 Components of ADCs
3.2.1.1 Antibody
3.2.1.2 Cytotoxin
3.2.1.3 Linker
3.3. Advantages of ADCs Over Conventional Therapeutics
3.4. ADC Linker Technologies
3.4.1. Non-cleavable Linkers
3.4.2. Cleavable Linkers
3.4. ADC Conjugation Technologies
3.4.1. Chemical Conjugation
3.4.2. Enzymatic Conjugation
3.5. Future Perspectives
4. ADC LINKER AND CONJUGATION TECHNOLOGIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. ADC Linker and Conjugation Technologies: Overall Market Landscape
4.2.1. Analysis by Type of Technology
4.2.2. Analysis by Availability of Licensing
4.3. ADC Conjugation Technologies
4.3.1. Analysis by Generation of Technology
4.3.2. Analysis by Site Specificity
4.3.3. Analysis by Type of Conjugation
4.3.4. Analysis by Drug Antibody Ratio
4.3.5. Analysis by Compatible Linker
4.3.6. Analysis by Conjugation Chemistry
4.3.7. Analysis by Conjugation Site
4.4. ADC Linker and ADC Linker-Payload Technologies
4.4.1. Analysis by Type of Linker
4.5. ADC Linker and Conjugation Technology Providers
4.5.1. Analysis by Year of Establishment
4.5.2. Analysis by Company Size
4.5.3. Analysis by Location of Headquarters
4.5.4. Analysis by Year of Establishment and Location of Headquarters
4.5.5. Analysis by Company Size and Location of Headquarters
4.6. ADC Conjugation Technologies Service Providers
5. TECHNOLOGY COMPETITIVENESS ANALYSIS
5.1 Chapter Overview
5.2 Assumptions and Key Parameters
5.3 Methodology
5.4 ADC Linker and Conjugation Technologies: Technology Competitiveness Analysis
5.4.1 Technologies Offered by Small Companies
5.4.2 Technologies Offered by Mid-sized Companies
5.4.3 Technologies Offered by Large Companies
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Companies Headquartered in North America
6.2.1. Ambrx
6.2.1.2. Company Overview
6.2.1.3. Financial Information
6.2.1.4. Technology Portfolio
6.2.1.5. Recent Developments and Future outlook
6.2.2. Catalent Biologics
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Technology Portfolio
6.2.2.4. Recent Developments and Future outlook
6.2.3. Mersana Therapeutics
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Technology Portfolio
6.2.3.4. Recent Developments and Future outlook
6.2.4. Seagen
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Technology Portfolio
6.2.4.4. Recent Developments and Future outlook
6.2.5. Sutro Biopharma
6.2.5.1. Company Overview
6.2.5.2. Financial Information
6.2.5.3. Technology Portfolio
6.2.5.4. Recent Developments and Future outlook
6.3. Companies Headquartered in Europe
6.3.1. Antikor Biopharma
6.3.1.1. Company Overview
6.3.1.2. Technology Portfolio
6.3.1.3. Recent Developments and Future outlook
6.3.2. Iksuda Therapeutics
6.3.2.1. Company Overview
6.3.2.2. Technology Portfolio
6.3.2.3. Recent Developments and Future outlook
6.3.3. Heidelberg Pharma
6.3.3.1. Company Overview
6.3.3.2. Financial Information
6.3.3.3. Technology Portfolio
6.3.3.4. Recent Developments and Future outlook
6.3.4. LinXis Biopharmaceuticals
6.3.4.1. Company Overview
6.3.4.2. Technology Portfolio
6.3.4.3. Recent Developments and Future outlook
6.3.5. NBE-Therapeutics
6.3.5.1. Company Overview
6.3.5.2. Technology Portfolio
6.3.5.3. Recent Developments and Future outlook
6.4. Companies Headquartered in Asia-Pacific and Rest of the World
6.4.1. Alteogen
6.4.1.1. Company Overview
6.4.1.2. Technology Portfolio
6.4.1.3. Recent Developments and Future outlook
6.5.2. LegoChem Biosciences
6.5.2.1. Company Overview
6.5.2.2. Technology Portfolio
6.5.2.3. Recent Developments and Future outlook
7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. ADC Linker and Conjugation Technologies: Patent Analysis
7.3.1. Analysis by Publication Year
7.3.2. Analysis by Application Year
7.3.3. Analysis by Annual Number of Granted Patents and Patent Applications
7.3.4. Analysis by Patent Jurisdiction
7.3.5. Analysis by CPC Symbols and Sections
7.3.6. Analysis by Type of Applicant
7.3.7. Leading Industry Players: Analysis by Number of Patents
7.3.8. Leading Non-Industry Players: Analysis by Number of Patents
7.3.9. Leading Patent Assignees: Analysis by Number of Patents
7.4. Patent Benchmarking Analysis
7.4.1. Analysis by Patent Characteristics
7.5. Patent Valuation
7.6. Leading Patents by Number of Citations
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. ADC Linker and Conjugation Technologies: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partnership
8.3.4. Analysis by Type of Partnership and Generation of Technology
8.3.5. Analysis by Type of Partnership and Type of Linker
8.3.6. Analysis by Type of Partnership and Type of Conjugation
8.3.7. Analysis by Type of Partner
8.3.8. Analysis by Year of Partnership and Type of Partner
8.3.9. Analysis by Type of Partnership and Type of Partner
8.3.10. Analysis by Target Therapeutic Area(s)
8.3.11. Most Active Players: Analysis by Number of Partnerships
8.3.12. Most Popular Technologies: Analysis by Number of Partnerships
8.4. Regional Analysis
8.4.1. Local and International Agreements
8.4.12. Intercontinental and Intracontinental Agreements
9. BUSINESS MODEL ANALYSIS
9.1. Chapter Overview
9.2 Business Strategies
9.4. ADC Linker and Conjugation Technology Providers: Business Strategy Analysis
9.4.1. Analysis by Purpose of Partnership
9.4.2. Analysis by Year of Partnership and Purpose of Partnership
9.4.3. Analysis by Type of Business Strategy Adopted
9.4.4. Analysis by Purpose of Partnership and Type of Business Strategy Adopted
9.4.5. Analysis by Upfront and Milestone Payments
9.4.6. Analysis by Type of Business Strategy Adopted and Deal Value
9.5. Most Active Players: Analysis by Number of Partnerships
9.5.1. Synaffix
9.5.1.1. Analysis by Purpose of Partnership
9.5.1.2. Analysis of Technology Out-Licensing Deals by Deal Value
9.5.2. LegoChem Biosciences
9.5.2.1. Analysis by Purpose of Partnership
9.5.2.2. Analysis by Year of Partnership and Business Strategy Adopted
9.5.2.3. Analysis of Technology Out-Licensing Deals by Amount of Investment
9.5.3. Catalent Biologics
9.5.3.1. Analysis by Purpose of Partnership
9.5.3.2. Analysis by Year of Partnership and Business Strategy Adopted
9.5.4. Sutro Biopharma
9.5.4.1. Analysis by Purpose of Partnership
9.5.4.2. Analysis by Year of Partnership and Business Strategy Adopted
9.5.4.3. Analysis of Technology Out-Licensing Deals by Deal Value
9.5.5. Heidelberg Pharma
9.5.5.1. Analysis by Purpose of Partnership
9.5.5.2. Analysis by Year of Partnership and Business Strategy Adopted
9.5.6. Mersana Therapeutics
9.5.6.1. Analysis by Purpose of Partnership
9.5.6.2. Analysis by Year of Partnership and Business Strategy Adopted
9.7. Concluding Remarks
10. LIKELY PARTNERS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions / Key Parameters
10.3. Scope and Methodology
10.4. Potential Strategic Partners in North America
10.4.1. Most Likely Partners
10.4.2. Likely Partners
10.4.3. Less Likely Partners
10.4.4. Least Likely Partners
10.5. Potential Strategic Partners in Europe
10.5.1. Most Likely Partners
10.5.2. Likely Partners
10.5.3. Less Likely Partners
10.5.4. Least Likely Partners
10.6. Potential Strategic Partners in Asia-Pacific and Rest of the World
10.6.1. Most Likely Partners
10.6.2. Likely Partners
10.6.3. Less Likely Partners
10.6.4. Least Likely Partners
11. BRAND POSITIONING ANALYSIS
11.1. Chapter Overview
11.2 Scope and Methodology
11.3. Key Parameters
11.4. Brand Positioning Matrix: ADC Conjugation Technology Providers
11.4.1. Brand Positioning Matrix: Abzena
11.4.2. Brand Positioning Matrix: Ambrx
11.4.3. Brand Positioning Matrix: Byondis
11.4.4. Brand Positioning Matrix: Creative Biolabs
11.4.5. Brand Positioning Matrix: Eisai
11.4.6. Brand Positioning Matrix: Mersana Therapeutics
11.4.7. Brand Positioning Matrix: Sorrento Therapeutics
11.4.8. Brand Positioning Matrix: Tubulis
12. ADC THERAPEUTICS: MARKET LANDSCAPE
12.1. Chapter Overview
12.2. Antibody Drug Conjugates: Therapies Pipeline
12.2.1. Analysis by Stage of Development
12.2.2. Analysis by Target Disease Indication(s)
12.2.3. Analysis by Therapeutic Area(s)
12.2.4. Analysis by Line of Treatment
12.2.5. Analysis by Dosing Frequency
12.2.6. Analysis by Type of Therapy
12.2.7. Analysis by Target Antigen
12.2.8. Analysis by Antibody Isotype
12.2.9. Analysis by Type of Payload / Cytotoxin / Warhead
12.2.10. Analysis by Type of Payload
12.2.11. Analysis by Linker
12.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)
12.3. Antibody Drug Conjugate: List of Developers
12.3.1. Analysis by Year of Establishment
12.3.2. Analysis by Company Size
12.3.3. Analysis by Location of Headquarters
12.3.4. Analysis by Company size and Location of Headquarters
12.3.5. Most Active Players: Analysis by Number of Therapies
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions
13.3. Forecast Methodology
13.4. Global ADC Linker and Conjugation Technologies Market, Historical, Base and Forecasted Scenario, 2017-2035
13.4.1. ADC Linker and Conjugation Technologies Market: Distribution by Generation of Technology, 2023 and 2035
13.4.1.1. ADC Linker and Conjugation Technologies Market for Third-Generation Technologies 2023-2035
13.4.1.2. ADC Linker and Conjugation Technologies Market for Second-Generation Technologies 2023-2035
13.4.1.3. ADC Linker and Conjugation Technologies Market for Next-Generation Technologies, 2023-2035
13.4.2. ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2023 and 2035
13.4.2.1. ADC Linker and Conjugation Technologies Market for Chemical Conjugation, 2023-2035
13.4.2.2. ADC Linker and Conjugation Technologies Market for Chemoenzymatic Conjugation, 2023-2035
13.4.2.3. ADC Linker and Conjugation Technologies Market for Enzymatic Conjugation, 2023-2035
13.4.3. ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2023 and 2035
13.4.3.1. ADC Linker and Conjugation Technologies Market for Cleavable Linkers, 2023-2035
13.4.3.2. ADC Linker and Conjugation Technologies Market for Non-Cleavable Linkers, 2023-2035
13.4.4. ADC Linker and Conjugation Technologies Market: Distribution by Type of Payment Model Adopted, 2023 and 2035
13.4.4.1. ADC Linker and Conjugation Technologies Market for Upfront Payments, 2023-2035
13.4.4.2. ADC Linker and Conjugation Technologies Market for Milestone Payments, 2023-2035
13.4.5. ADC Linker and Conjugation Technologies Market: Distribution by Key Geographical Regions, 2023 and 2035
13.4.5.1. ADC Linker and Conjugation Technologies Market in North America, 2023-2035
13.4.5.1.1. ADC Linker and Conjugation Technologies Market in North America: Distribution by Generation of Technology, 2023-2035
13.4.5.1.2. ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2023-2035
13.4.5.1.3. ADC Linker and Conjugation Technologies Market in North America: Distribution by Type Linker, 2023-2035
13.4.5.2. ADC Linker and Conjugation Technologies Market in Europe, 2023-2035
13.4.5.2.1. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Generation of Technology, 2023-2035
13.4.5.2.2. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2023-2035
13.4.5.2.3. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type Linker, 2023-2035
13.4.5.3. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World, 2023-2035
13.4.5.3.1. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Generation of Technology, 2023-2035
13.4.5.3.2. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Conjugation, 2023-2035
13.4.5.3.3. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Linker, 2023-2035
13.5. Concluding Remarks
14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Abzena
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Saptarshi Ghosh (Scientist II)
14.3. MedLink Therapeutics
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Jiaqiang Cai (Co-Founder and Chief Scientific Officer)
14.4. Merck KGaA
14.4.1. Company Snapshot
14.4.2. Interview Transcript: Kai Uhrig (Head of Strategy and Business Development)
14.5. Singzyme
14.5.1. Company Snapshot
14.5.2. Interview Transcript: Cedric Lizin (Board Member)
14.6. Ajinomoto
14.6.1. Company Snapshot
14.6.2. Interview Transcript: Okuzumi-Tatsuya (General Manager, Research and Development), Brian Mendelsohn (Director of ADC Process Development and Tech Transfer)
14.7. Eucodis Bioscience
14.7.1. Company Snapshot
14.7.2. Interview Transcript: Jan Modregger (Head of Research and Development)
14.8. NBE-Therapeutics
14.8.1. Company Snapshot
14.8.2. Interview Transcript: Wouter Verhoeven (Former Chief Business Officer)
14.9. Shanghai Miracogen
14.9.1. Company Snapshot
14.9.2. Interview Transcript: Mary Chaohong Hu (Chief Executive Officer)
14.10. Synaffix
14.10.1. Company Snapshot
14.10.2. Interview Transcript: Floris van Delft (Chief Scientific Officer)
15. CONCLUDING REMARKS
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2 Antibody Drug Conjugates (ADCs)
3.2.1 Components of ADCs
3.2.1.1 Antibody
3.2.1.2 Cytotoxin
3.2.1.3 Linker
3.3. Advantages of ADCs Over Conventional Therapeutics
3.4. ADC Linker Technologies
3.4.1. Non-cleavable Linkers
3.4.2. Cleavable Linkers
3.4. ADC Conjugation Technologies
3.4.1. Chemical Conjugation
3.4.2. Enzymatic Conjugation
3.5. Future Perspectives
4. ADC LINKER AND CONJUGATION TECHNOLOGIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. ADC Linker and Conjugation Technologies: Overall Market Landscape
4.2.1. Analysis by Type of Technology
4.2.2. Analysis by Availability of Licensing
4.3. ADC Conjugation Technologies
4.3.1. Analysis by Generation of Technology
4.3.2. Analysis by Site Specificity
4.3.3. Analysis by Type of Conjugation
4.3.4. Analysis by Drug Antibody Ratio
4.3.5. Analysis by Compatible Linker
4.3.6. Analysis by Conjugation Chemistry
4.3.7. Analysis by Conjugation Site
4.4. ADC Linker and ADC Linker-Payload Technologies
4.4.1. Analysis by Type of Linker
4.5. ADC Linker and Conjugation Technology Providers
4.5.1. Analysis by Year of Establishment
4.5.2. Analysis by Company Size
4.5.3. Analysis by Location of Headquarters
4.5.4. Analysis by Year of Establishment and Location of Headquarters
4.5.5. Analysis by Company Size and Location of Headquarters
4.6. ADC Conjugation Technologies Service Providers
5. TECHNOLOGY COMPETITIVENESS ANALYSIS
5.1 Chapter Overview
5.2 Assumptions and Key Parameters
5.3 Methodology
5.4 ADC Linker and Conjugation Technologies: Technology Competitiveness Analysis
5.4.1 Technologies Offered by Small Companies
5.4.2 Technologies Offered by Mid-sized Companies
5.4.3 Technologies Offered by Large Companies
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Companies Headquartered in North America
6.2.1. Ambrx
6.2.1.2. Company Overview
6.2.1.3. Financial Information
6.2.1.4. Technology Portfolio
6.2.1.5. Recent Developments and Future outlook
6.2.2. Catalent Biologics
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Technology Portfolio
6.2.2.4. Recent Developments and Future outlook
6.2.3. Mersana Therapeutics
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Technology Portfolio
6.2.3.4. Recent Developments and Future outlook
6.2.4. Seagen
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Technology Portfolio
6.2.4.4. Recent Developments and Future outlook
6.2.5. Sutro Biopharma
6.2.5.1. Company Overview
6.2.5.2. Financial Information
6.2.5.3. Technology Portfolio
6.2.5.4. Recent Developments and Future outlook
6.3. Companies Headquartered in Europe
6.3.1. Antikor Biopharma
6.3.1.1. Company Overview
6.3.1.2. Technology Portfolio
6.3.1.3. Recent Developments and Future outlook
6.3.2. Iksuda Therapeutics
6.3.2.1. Company Overview
6.3.2.2. Technology Portfolio
6.3.2.3. Recent Developments and Future outlook
6.3.3. Heidelberg Pharma
6.3.3.1. Company Overview
6.3.3.2. Financial Information
6.3.3.3. Technology Portfolio
6.3.3.4. Recent Developments and Future outlook
6.3.4. LinXis Biopharmaceuticals
6.3.4.1. Company Overview
6.3.4.2. Technology Portfolio
6.3.4.3. Recent Developments and Future outlook
6.3.5. NBE-Therapeutics
6.3.5.1. Company Overview
6.3.5.2. Technology Portfolio
6.3.5.3. Recent Developments and Future outlook
6.4. Companies Headquartered in Asia-Pacific and Rest of the World
6.4.1. Alteogen
6.4.1.1. Company Overview
6.4.1.2. Technology Portfolio
6.4.1.3. Recent Developments and Future outlook
6.5.2. LegoChem Biosciences
6.5.2.1. Company Overview
6.5.2.2. Technology Portfolio
6.5.2.3. Recent Developments and Future outlook
7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. ADC Linker and Conjugation Technologies: Patent Analysis
7.3.1. Analysis by Publication Year
7.3.2. Analysis by Application Year
7.3.3. Analysis by Annual Number of Granted Patents and Patent Applications
7.3.4. Analysis by Patent Jurisdiction
7.3.5. Analysis by CPC Symbols and Sections
7.3.6. Analysis by Type of Applicant
7.3.7. Leading Industry Players: Analysis by Number of Patents
7.3.8. Leading Non-Industry Players: Analysis by Number of Patents
7.3.9. Leading Patent Assignees: Analysis by Number of Patents
7.4. Patent Benchmarking Analysis
7.4.1. Analysis by Patent Characteristics
7.5. Patent Valuation
7.6. Leading Patents by Number of Citations
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. ADC Linker and Conjugation Technologies: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partnership
8.3.4. Analysis by Type of Partnership and Generation of Technology
8.3.5. Analysis by Type of Partnership and Type of Linker
8.3.6. Analysis by Type of Partnership and Type of Conjugation
8.3.7. Analysis by Type of Partner
8.3.8. Analysis by Year of Partnership and Type of Partner
8.3.9. Analysis by Type of Partnership and Type of Partner
8.3.10. Analysis by Target Therapeutic Area(s)
8.3.11. Most Active Players: Analysis by Number of Partnerships
8.3.12. Most Popular Technologies: Analysis by Number of Partnerships
8.4. Regional Analysis
8.4.1. Local and International Agreements
8.4.12. Intercontinental and Intracontinental Agreements
9. BUSINESS MODEL ANALYSIS
9.1. Chapter Overview
9.2 Business Strategies
9.4. ADC Linker and Conjugation Technology Providers: Business Strategy Analysis
9.4.1. Analysis by Purpose of Partnership
9.4.2. Analysis by Year of Partnership and Purpose of Partnership
9.4.3. Analysis by Type of Business Strategy Adopted
9.4.4. Analysis by Purpose of Partnership and Type of Business Strategy Adopted
9.4.5. Analysis by Upfront and Milestone Payments
9.4.6. Analysis by Type of Business Strategy Adopted and Deal Value
9.5. Most Active Players: Analysis by Number of Partnerships
9.5.1. Synaffix
9.5.1.1. Analysis by Purpose of Partnership
9.5.1.2. Analysis of Technology Out-Licensing Deals by Deal Value
9.5.2. LegoChem Biosciences
9.5.2.1. Analysis by Purpose of Partnership
9.5.2.2. Analysis by Year of Partnership and Business Strategy Adopted
9.5.2.3. Analysis of Technology Out-Licensing Deals by Amount of Investment
9.5.3. Catalent Biologics
9.5.3.1. Analysis by Purpose of Partnership
9.5.3.2. Analysis by Year of Partnership and Business Strategy Adopted
9.5.4. Sutro Biopharma
9.5.4.1. Analysis by Purpose of Partnership
9.5.4.2. Analysis by Year of Partnership and Business Strategy Adopted
9.5.4.3. Analysis of Technology Out-Licensing Deals by Deal Value
9.5.5. Heidelberg Pharma
9.5.5.1. Analysis by Purpose of Partnership
9.5.5.2. Analysis by Year of Partnership and Business Strategy Adopted
9.5.6. Mersana Therapeutics
9.5.6.1. Analysis by Purpose of Partnership
9.5.6.2. Analysis by Year of Partnership and Business Strategy Adopted
9.7. Concluding Remarks
10. LIKELY PARTNERS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions / Key Parameters
10.3. Scope and Methodology
10.4. Potential Strategic Partners in North America
10.4.1. Most Likely Partners
10.4.2. Likely Partners
10.4.3. Less Likely Partners
10.4.4. Least Likely Partners
10.5. Potential Strategic Partners in Europe
10.5.1. Most Likely Partners
10.5.2. Likely Partners
10.5.3. Less Likely Partners
10.5.4. Least Likely Partners
10.6. Potential Strategic Partners in Asia-Pacific and Rest of the World
10.6.1. Most Likely Partners
10.6.2. Likely Partners
10.6.3. Less Likely Partners
10.6.4. Least Likely Partners
11. BRAND POSITIONING ANALYSIS
11.1. Chapter Overview
11.2 Scope and Methodology
11.3. Key Parameters
11.4. Brand Positioning Matrix: ADC Conjugation Technology Providers
11.4.1. Brand Positioning Matrix: Abzena
11.4.2. Brand Positioning Matrix: Ambrx
11.4.3. Brand Positioning Matrix: Byondis
11.4.4. Brand Positioning Matrix: Creative Biolabs
11.4.5. Brand Positioning Matrix: Eisai
11.4.6. Brand Positioning Matrix: Mersana Therapeutics
11.4.7. Brand Positioning Matrix: Sorrento Therapeutics
11.4.8. Brand Positioning Matrix: Tubulis
12. ADC THERAPEUTICS: MARKET LANDSCAPE
12.1. Chapter Overview
12.2. Antibody Drug Conjugates: Therapies Pipeline
12.2.1. Analysis by Stage of Development
12.2.2. Analysis by Target Disease Indication(s)
12.2.3. Analysis by Therapeutic Area(s)
12.2.4. Analysis by Line of Treatment
12.2.5. Analysis by Dosing Frequency
12.2.6. Analysis by Type of Therapy
12.2.7. Analysis by Target Antigen
12.2.8. Analysis by Antibody Isotype
12.2.9. Analysis by Type of Payload / Cytotoxin / Warhead
12.2.10. Analysis by Type of Payload
12.2.11. Analysis by Linker
12.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)
12.3. Antibody Drug Conjugate: List of Developers
12.3.1. Analysis by Year of Establishment
12.3.2. Analysis by Company Size
12.3.3. Analysis by Location of Headquarters
12.3.4. Analysis by Company size and Location of Headquarters
12.3.5. Most Active Players: Analysis by Number of Therapies
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions
13.3. Forecast Methodology
13.4. Global ADC Linker and Conjugation Technologies Market, Historical, Base and Forecasted Scenario, 2017-2035
13.4.1. ADC Linker and Conjugation Technologies Market: Distribution by Generation of Technology, 2023 and 2035
13.4.1.1. ADC Linker and Conjugation Technologies Market for Third-Generation Technologies 2023-2035
13.4.1.2. ADC Linker and Conjugation Technologies Market for Second-Generation Technologies 2023-2035
13.4.1.3. ADC Linker and Conjugation Technologies Market for Next-Generation Technologies, 2023-2035
13.4.2. ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2023 and 2035
13.4.2.1. ADC Linker and Conjugation Technologies Market for Chemical Conjugation, 2023-2035
13.4.2.2. ADC Linker and Conjugation Technologies Market for Chemoenzymatic Conjugation, 2023-2035
13.4.2.3. ADC Linker and Conjugation Technologies Market for Enzymatic Conjugation, 2023-2035
13.4.3. ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2023 and 2035
13.4.3.1. ADC Linker and Conjugation Technologies Market for Cleavable Linkers, 2023-2035
13.4.3.2. ADC Linker and Conjugation Technologies Market for Non-Cleavable Linkers, 2023-2035
13.4.4. ADC Linker and Conjugation Technologies Market: Distribution by Type of Payment Model Adopted, 2023 and 2035
13.4.4.1. ADC Linker and Conjugation Technologies Market for Upfront Payments, 2023-2035
13.4.4.2. ADC Linker and Conjugation Technologies Market for Milestone Payments, 2023-2035
13.4.5. ADC Linker and Conjugation Technologies Market: Distribution by Key Geographical Regions, 2023 and 2035
13.4.5.1. ADC Linker and Conjugation Technologies Market in North America, 2023-2035
13.4.5.1.1. ADC Linker and Conjugation Technologies Market in North America: Distribution by Generation of Technology, 2023-2035
13.4.5.1.2. ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2023-2035
13.4.5.1.3. ADC Linker and Conjugation Technologies Market in North America: Distribution by Type Linker, 2023-2035
13.4.5.2. ADC Linker and Conjugation Technologies Market in Europe, 2023-2035
13.4.5.2.1. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Generation of Technology, 2023-2035
13.4.5.2.2. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2023-2035
13.4.5.2.3. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type Linker, 2023-2035
13.4.5.3. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World, 2023-2035
13.4.5.3.1. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Generation of Technology, 2023-2035
13.4.5.3.2. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Conjugation, 2023-2035
13.4.5.3.3. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Linker, 2023-2035
13.5. Concluding Remarks
14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Abzena
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Saptarshi Ghosh (Scientist II)
14.3. MedLink Therapeutics
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Jiaqiang Cai (Co-Founder and Chief Scientific Officer)
14.4. Merck KGaA
14.4.1. Company Snapshot
14.4.2. Interview Transcript: Kai Uhrig (Head of Strategy and Business Development)
14.5. Singzyme
14.5.1. Company Snapshot
14.5.2. Interview Transcript: Cedric Lizin (Board Member)
14.6. Ajinomoto
14.6.1. Company Snapshot
14.6.2. Interview Transcript: Okuzumi-Tatsuya (General Manager, Research and Development), Brian Mendelsohn (Director of ADC Process Development and Tech Transfer)
14.7. Eucodis Bioscience
14.7.1. Company Snapshot
14.7.2. Interview Transcript: Jan Modregger (Head of Research and Development)
14.8. NBE-Therapeutics
14.8.1. Company Snapshot
14.8.2. Interview Transcript: Wouter Verhoeven (Former Chief Business Officer)
14.9. Shanghai Miracogen
14.9.1. Company Snapshot
14.9.2. Interview Transcript: Mary Chaohong Hu (Chief Executive Officer)
14.10. Synaffix
14.10.1. Company Snapshot
14.10.2. Interview Transcript: Floris van Delft (Chief Scientific Officer)
15. CONCLUDING REMARKS
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
